• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.

作者信息

Bhoori Sherrie, Mazzaferro Vincenzo

机构信息

Hepatology, Hepato-pancreato-biliary Surgery and Liver Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.

Department of Oncology, University of Milan, Milan 20133, Italy.

出版信息

Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.

DOI:10.1016/S1470-2045(20)30211-4
PMID:32502436
Abstract
摘要

相似文献

1
Combined immunotherapy and VEGF-antagonist in hepatocellular carcinoma: a step forward.联合免疫疗法与血管内皮生长因子拮抗剂治疗肝细胞癌：向前迈进的一步
Lancet Oncol. 2020 Jun;21(6):740-741. doi: 10.1016/S1470-2045(20)30211-4.
2
Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.贝伐单抗和雷帕霉素在小鼠肝癌模型中诱导生长抑制。
J Hepatol. 2008 Jul;49(1):52-60. doi: 10.1016/j.jhep.2008.02.022. Epub 2008 Apr 28.
3
[Antiangiogenic therapy for gastrointestinal tumors].[胃肠道肿瘤的抗血管生成治疗]
Orv Hetil. 2008 Dec 7;149(49):2317-24. doi: 10.1556/OH.2008.28496.
4
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.阿替利珠单抗与贝伐单抗治疗肝细胞癌
N Engl J Med. 2020 Aug 13;383(7):693-694. doi: 10.1056/NEJMc2021840.
5
Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.靶向血管内皮生长因子的单克隆抗体：癌症治疗的现状与未来挑战
BioDrugs. 2009;23(5):289-304. doi: 10.2165/11317600-000000000-00000.
6
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma. Reply.阿替利珠单抗和贝伐单抗治疗肝细胞癌。回复。
N Engl J Med. 2020 Aug 13;383(7):695. doi: 10.1056/NEJMc2021840.
7
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌
Lancet Oncol. 2020 Sep;21(9):e412. doi: 10.1016/S1470-2045(20)30430-7.
8
Atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma - Authors' replys.阿替利珠单抗联合贝伐单抗治疗不可切除肝细胞癌——作者回复
Lancet Oncol. 2020 Sep;21(9):e413. doi: 10.1016/S1470-2045(20)30476-9.
9
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.阿替利珠单抗和贝伐珠单抗治疗肝细胞癌
N Engl J Med. 2020 Aug 13;383(7):694-695. doi: 10.1056/NEJMc2021840.
10
Atezolizumab and Bevacizumab in Hepatocellular Carcinoma.阿替利珠单抗与贝伐珠单抗治疗肝细胞癌
N Engl J Med. 2020 Aug 13;383(7):694. doi: 10.1056/NEJMc2021840.

引用本文的文献

1
ElF5B as a prognostic biomarker and its correlation with infiltrating immune cells in liver cancer.ElF5B作为一种预后生物标志物及其与肝癌中浸润免疫细胞的相关性。
Genes Genomics. 2025 Aug 25. doi: 10.1007/s13258-025-01671-6.
2
Global perspectives and hotspots of VEGF signaling pathway in liver disease from 2008 to 2023: A bibliometric analysis and visualization.2008年至2023年肝脏疾病中VEGF信号通路的全球视角与热点：文献计量分析与可视化
Heliyon. 2024 Dec 19;11(1):e41346. doi: 10.1016/j.heliyon.2024.e41346. eCollection 2025 Jan 15.
3
Comprehensive analysis of CXCL10 and MIP-3a reveals their potential clinical application in hepatocellular carcinoma.
对CXCL10和MIP-3a的综合分析揭示了它们在肝细胞癌中的潜在临床应用。
Transl Oncol. 2024 Oct;48:102071. doi: 10.1016/j.tranon.2024.102071. Epub 2024 Aug 3.
4
Cross-talk between cancer stem cells and immune cells: potential therapeutic targets in the tumor immune microenvironment.肿瘤免疫微环境中癌细胞与免疫细胞的串扰：潜在的治疗靶点。
Mol Cancer. 2023 Feb 21;22(1):38. doi: 10.1186/s12943-023-01748-4.
5
Recent Perspectives on the Mechanism of Recurrence After Ablation of Hepatocellular Carcinoma: A Mini-Review.肝细胞癌消融术后复发机制的最新观点：一篇综述。
Front Oncol. 2022 Aug 23;12:895678. doi: 10.3389/fonc.2022.895678. eCollection 2022.
6
SHR6390 Combined with Cabozantinib Inhibits Tumor Progression in the Hepatocellular Carcinoma Mouse Model.SHR6390 联合卡博替尼抑制肝癌小鼠模型中的肿瘤进展。
Curr Gene Ther. 2024;24(5):453-464. doi: 10.2174/1566523222666220825110147.
7
Risk of Adverse Events in Cancer Patients Receiving Nivolumab With Ipilimumab: A Meta-Analysis.接受纳武利尤单抗联合伊匹木单抗治疗的癌症患者发生不良事件的风险：一项荟萃分析。
Front Oncol. 2022 Jun 23;12:877434. doi: 10.3389/fonc.2022.877434. eCollection 2022.
8
Drug delivery strategy in hepatocellular carcinoma therapy.肝癌治疗中的药物输送策略。
Cell Commun Signal. 2022 Mar 5;20(1):26. doi: 10.1186/s12964-021-00796-x.
9
Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges.肝细胞癌中的免疫检查点抑制剂：当前进展与挑战
Front Oncol. 2021 Oct 22;11:737497. doi: 10.3389/fonc.2021.737497. eCollection 2021.
10
Apatinib suppresses the migration, invasion and angiogenesis of hepatocellular carcinoma cells by blocking VEGF and PI3K/AKT signaling pathways.阿帕替尼通过阻断 VEGF 和 PI3K/AKT 信号通路抑制肝癌细胞的迁移、侵袭和血管生成。
Mol Med Rep. 2021 Jun;23(6). doi: 10.3892/mmr.2021.12068. Epub 2021 Apr 13.